Related Experiment Videos
Lamivudine for hepatitis B in clinical practice
1Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida, USA.
Journal of Medical Virology
|June 22, 2000
Summary
Lamivudine is an effective oral antiviral for chronic hepatitis B virus (HBV) infection, suppressing viral replication and improving liver health. It is well-tolerated and a preferred treatment option for most patients requiring therapy.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis B virus (HBV) infection poses a significant global health burden.
- Effective antiviral therapies are crucial for managing HBV and preventing disease progression.
Purpose of the Study:
- To evaluate the efficacy and tolerability of lamivudine as an oral antiviral therapy for chronic hepatitis B.
- To assess lamivudine's impact on viral replication, serological markers, liver disease, and patient outcomes.
Main Methods:
- Systematic review of studies investigating lamivudine in various patient groups with chronic HBV.
- Analysis of viral DNA levels, hepatitis B e antigen (HBeAg) seroconversion, alanine transaminase (ALT) normalization, and progression to cirrhosis.
Main Results:
- Lamivudine effectively suppresses HBV DNA and enhances HBeAg seroconversion.
- Treatment leads to normalization of ALT levels and reduces the risk of cirrhosis.
- It is effective in treatment-naïve patients, those with prior interferon (IFN) alpha failure, decompensated liver disease, and post-transplantation.
Conclusions:
- Lamivudine is a potent, well-tolerated, once-daily oral antiviral for chronic hepatitis B.
- It demonstrates significant clinical benefits, including viral suppression and improved liver histology.
- Lamivudine is considered the drug of choice for most patients requiring treatment for chronic hepatitis B.